Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. (Q44248315)

1 December 2017

Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. (English)

1 reference

1 December 2017

1 reference

Juliana Chung-ngor Chan

7

1 reference

1 December 2017

8

1 reference

1 December 2017

de Zeeuw D

1

1 reference

1 December 2017

Ramjit D

2

1 reference

1 December 2017

Zhang Z

3

1 reference

1 December 2017

Ribeiro AB

4

1 reference

1 December 2017

Kurokawa K

5

1 reference

1 December 2017

Lash JP

6

1 reference

1 December 2017

Brenner BM

9

1 reference

1 December 2017

Shahinfar S

10

1 reference

1 December 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

1 December 2017

1 reference

1 December 2017

69

1 reference

1 December 2017

9

1 reference

1 December 2017

1675-1682

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5000326

1 December 2017

0 references

cites work

Racial differences in the incidence of treatment for end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

The need and demand for renal replacement therapy in ethnic minorities in England

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Ethnic disparities in diabetic complications in an insured population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Excess incidence of treatment of end-stage renal disease in Mexican Americans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Diabetic nephropathy: prevention and treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Clinical practice. Nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Management of dyslipidemia in children and adolescents with diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Predicting diabetic nephropathy in insulin-dependent patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Effects of blood pressure control on progressive renal disease in blacks and whites. Modification of Diet in Renal Disease Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Racial differences in the prevalence of microalbuminuria in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Comparison of prevalence and risk factors for microalbuminuria in South Asians and Europeans with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Ethnic differences in the prevalence of hypertension and proteinuria in NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Prevalence of proteinuria/microalbuminuria in an elderly urban, biethnic community

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Proteinuria in Mexican Americans and non-Hispanic whites with NIDDM.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Importance of baseline distribution of proteinuria in renal outcomes trials: lessons from the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Effective Antihypertensive Treatment Postpones Renal Insufficiency in Diabetic Nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Etiology and prognostic significance of albuminuria in diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

The impact of ethnicity on response to antihypertensive therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000326

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5000326

1 reference

release_wxbtokk3zzh4tmdvcnuikszjza

1 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wxbtokk3zzh4tmdvcnuikszjza

24 November 2022

mapped directly with Wikidata item

1 reference